Annovis Bio, Inc. Balance Sheet
ANVS|6 years of annual SEC 10-K data (FY2020-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 6 fiscal years. All figures from audited SEC 10-K filings.
Annovis Bio, Inc. had $21M in total assets and $17M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -9.28 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.5M | $10.6M | $5.8M | $28.4M | $45.7M | $8.1M |
| Current Assets | - | - | $10.2M | $36.0M | $46.0M | $8.1M |
| Total Assets | $21.1M | $13.9M | $10.2M | $36.0M | $46.0M | $8.1M |
| Current Liabilities | $3.6M | $3.9M | $4.3M | $7.7M | $1.5M | $578.4K |
| Shareholders' Equity | $16.9M | -$7.8M | $28.3M | $28.3M | $7.5M | -$8.6M |